Why the study?
Does empagliflozin reduce circulating monocyte-platelet aggregates in women with obesity and pre-diabetes?
Does empagliflozin reduce circulating monocyte-platelet aggregates in women with obesity and pre-diabetes?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This finding is significant because it's the first time this medication has been shown to have an immune effect at the cellular level with some specificity. If we understand how these medicines are reducing obesity-associated inflammation, heart disease and kidney disease, then we can identify the best patient for this treatment or discover other drug targets in that pathway that could really be beneficial.”
“There had been some suggestive studies in animals with these medications indicating they might be modulating the immune system - affecting inflammation - but that hadn't really been shown in humans. This study provides the first direct evidence of SGLT2 inhibitors altering human immune cells which may potentially reduce cardiovascular risk.”
Empagliflozin reduces pro-inflammatory monocyte-platelet aggregates and induces coordinated metabolic reprogramming in monocytes, highlighting a potential novel anti-inflammatory mechanism for its cardiovascular benefits.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Safa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: